Safety profile of once-weekly subcutaneous semaglutide in a real-world adult population with type 2 diabetes

被引：0
|
作者：
Yale, J. -F. [1 ]
Major-Pedersen, A. [2 ]
Catarig, A. -M. [3 ]
Jain, R. G. [4 ]
Menzen, M. [5 ]
Holmes, P. [6 ]
机构：
[1] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[2] Novo Nordisk AS, Global Safety, Soborg, Denmark
[3] Novo Nordisk AS, Soborg, Denmark
[4] Novo Nordisk Serv Ctr Private Ltd, Biostat, EPIP Area Whitefield, Mindcomp Tech Pk,2nd Phase, Bangalore, Karnataka, India
[5] Gemeinschaftskrankenhaus Bonn, Innere Med Diabetol, Bonn, Germany
[6] St Georges Med Practice, Yarm Rd, Darlington, Durham, England
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
670
引用
收藏
页码：S339 / S340
页数：2
相关论文
共 50 条
  • [1] Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D
    Yale, Jean-Francois
    Major-Pedersen, Atheline
    Catarig, Andrei-Mircea
    Jain, Rashmi
    Menzen, Markus
    Holmes, Patrick
    DIABETES, 2023, 72
  • [2] Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme
    Yale, Jean-Francois
    Major-Pedersen, Atheline
    Catarig, Andrei-Mircea
    Jain, Rashmi
    Menzen, Markus
    Holmes, Patrick
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4429 - 4440
  • [3] Efficacy and Safety of Once-Weekly Semaglutide in People with Type 1 Diabetes in Real-World Practice
    Bellido, Virginia
    Herguido, Noelia Gros
    Amuedo, Sandra
    Ariza, Luis Baena
    Alfonso, Soto M.
    DIABETES, 2023, 72
  • [4] Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
    Menzen, Markus
    Berentzen, Tina Landsvig
    Catarig, Andrei-Mircea
    Pieperhoff, Sebastian
    Simon, Joerg
    Jacob, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (04) : 205 - 215
  • [5] Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
    Garcia de Lucas, Maria Dolores
    Pablo Miramontes-Gonzalez, Jose
    Aviles-Bueno, Beatriz
    Isabel Jimenez-Millan, Ana
    Rivas-Ruiz, Francisco
    Perez-Belmonte, Luis M.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [6] Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic
    Hansen, Katrine B.
    Svendstrup, Mathilde
    Lund, Asger
    Knop, Filip K.
    Vilsboll, Tina
    Vestergaard, Henrik
    DIABETIC MEDICINE, 2021, 38 (10)
  • [7] Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)
    Mateos, Irene Caballero
    de Lucas, Maria Dolores Garcia
    Doulatram-Gamgaram, Viyey Kishore
    Moreno-Moreno, Paloma
    Jimenez-Millan, Ana Isabel
    Botana-Lopez, Manuel
    Merino-Torres, Juan Francisco
    Soto-Gonzalez, Alfonso
    Fernandez-Garcia, Jose Carlos
    Morales-Portillo, Cristobal
    NUTRIENTS, 2024, 16 (15)
  • [8] Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
    Tan, Xueying
    Cao, Xiaojing
    Zhou, Minzhi
    Zou, Ping
    Hu, Jingbo
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (09) : 1083 - 1089
  • [9] Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review
    Ruan, Zhen
    Jiang, Yixuan
    Shi, Honghao
    Jia, Ruxu
    Ung, Carolina Oi Lam
    Hu, Hao
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (02) : 161 - 176
  • [10] Real-world use of once-weekly semaglutide in type 2 diabetes: Results from the SURE UK study
    Holmes, P.
    Catarig, A. M.
    Clark, A.
    Erhan, U.
    Sathyapalan, T.
    DIABETIC MEDICINE, 2021, 38
12345